Trial · NCT02240238
Adverse events1,440
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,440
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 60 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 75 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 90 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 105 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 120 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 135 mg/m^2 | 1 | 9 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 150 mg/m^2 | 0 | 6 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 165 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 NC-6004 180 mg/m^2 | 0 | 1 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 2 Cohort 1 (NSCLC) | 0 | 34 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 2 Cohort 2 (Biliary Tract Cancer) | 0 | 50 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 2 Cohort 3 (Bladder Cancer) | 0 | 13 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 60 mg/m^2 | 0 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 75 mg/m^2 | 0 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 90 mg/m^2 | 1 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 105 mg/m^2 | 1 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 120 mg/m^2 | 1 | 1 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 135 mg/m^2 | 4 | 9 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 150 mg/m^2 | 4 | 6 | |
| other | Alanine aminotransferase increased | Investigations | Phase 1 NC-6004 165 mg/m^2 | 1 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02240238/events